ProKidney Corp. Class A Ordinary Shares (PROK)

About PROK

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserv…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

231

Website

prokidney.com/

Fundamentals

1-day range

$1.78$1.9

Market cap

$495.38M

P/E (trailing)

—

P/E (forward)

-3.12

EPS (trailing)

$-0.53

Dividend yield

—

Beta

1.87

Avg. volume

1.24M

Forecasts

6 analyst ratings

ProKidney Corp. Class A Ordinary Shares Competitors

Chosen by industry and closest market cap.

• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $495.38MP/E —
  $1.3$3.48
• VALN

  Valneva SE American Depositary Shares

  $6.43

  ▼ 2.13%
  Market cap $491.51MP/E —
  $2.03$5.34
• KYTX

  Kyverna Therapeutics Inc. Common Stock

  $8.36

  ▼ 3.24%
  Market cap $471.16MP/E —
  $3.55$13.67
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $528.15MP/E —
  $5.37$17.58
• AUTL

  Autolus Therapeutics plc American Depositary Share

  $2.34

  ▼ 1.06%
  Market cap $532.31MP/E —
  $1.18$2.58
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $532.82MP/E —
  $2.67$6.94
• CABA

  Cabaletta Bio Inc. Common Stock

  $3.11

  ▼ 7.99%
  Market cap $450.03MP/E —
  $1.4$4.23

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)
  SeekingAlpha · 8/14/2026
• ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate
  benzinga · 8/10/2026
• ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate
  Benzinga · 8/10/2026

• Brian JG Pereira · August 4, 2026 · Conversion

  675.2K
• Brian JG Pereira · August 4, 2026 · Conversion

  81.9K
• Locke Kenneth Thomas · July 1, 2026 · Grant

  750.0K
• Todd C. Girolamo · June 12, 2026 · Conversion

  163.9K
• Jimenez Santos Jose Ignacio · May 28, 2026 · Grant

  135.0K
• Fox Jennifer A. · May 28, 2026 · Grant

  135.0K
• Sinha Uma · May 28, 2026 · Grant

  135.0K
• Pablo G. Legorreta · May 28, 2026 · Grant

  135.0K
• Lotvin Alan · May 28, 2026 · Grant

  135.0K
• Brian JG Pereira · May 28, 2026 · Grant

  135.0K
• DOYLE WILLIAM F · May 28, 2026 · Grant

  135.0K
• Empresarial de Capitales S.A. de C.V. Control · April 28, 2026 · Conversion

  63.12M
• Coulston James · March 1, 2026 · Grant

  600.0K
• Darin J. Weber · March 1, 2026 · Grant

  400.0K
• Todd C. Girolamo · March 1, 2026 · Grant

  600.0K

Institutional Ownership

March 31, 2026

Total shares held

41.90M

Total value held

$74.42M

Institutional holders

66